Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
51 hedge funds and large institutions have $51M invested in Astria Therapeutics in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 6 closing their positions.
81% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $644K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 50 → 51 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 7.45% → 7.2% (-0.25%)
1% less capital invested
Capital invested by funds: $51.5M → $51M (-$489K)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.44M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$917K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$631K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$445K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$345K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$1.29M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$883K |
| 3 |
Renaissance Technologies
New York
|
-$669K |
| 4 |
Two Sigma Investments
New York
|
-$299K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$241K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Millennium Management
New York
| $78 | -$26.7K | -675 | -24% |
|
|
52
Blackstone Inc
New York
| – | -$1.29M | -33,470 | Closed |
|
|
WVP
53
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$883K | -22,904 | Closed |
|
|
54
Renaissance Technologies
New York
| – | -$669K | -17,341 | Closed |
|
|
PVI
55
Pura Vida Investments
New York
| – | -$119K | -3,085 | Closed |
|
56
Citadel Advisors
Miami,
Florida
| – | -$113K | -2,860 | Closed |
|
57
Jane Street
New York
| – | -$88K | -2,277 | Closed |
|
ATXS Hedge Fund Activity: Q3 2020 in Review
51 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2020, worth a combined $51M — down 0.95% from $51.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATXS positions and 6 closed out — a net gain of 1 holder — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $2.44M. The largest seller was Blackstone Inc, exiting entirely with an estimated $1.29M sold.
- 51 institutional investors held Astria Therapeutics (ATXS) as of Q3 2020, up from 50 in Q2 2020.
- Funds reported $51M of Astria Therapeutics stock for Q3 2020, down 0.95% quarter-over-quarter.
- 7 funds opened new Astria Therapeutics positions in Q3 2020 and 6 closed out, a net change of +1 holder.
- The largest Astria Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $2.44M added.
- The largest Astria Therapeutics seller in Q3 2020 was Blackstone Inc, an estimated $1.29M sold.
Based on aggregated 13F filings for Q3 2020.